NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Opus Genetics, Inc. (IRD) Stock Analysis

Opus Genetics, Inc. (IRD) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

IRD

$4.67

+$0.07 (+1.52%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare IRD with… →

IRD Key Statistics

As of Sep 4, 2026
Trading
Open
$4.53
Previous Close
$4.60
Day's Range
4.40–4.80
52-Week Range
1.24–5.81
Volume
2.24M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.58
Valuation
Market Cap
$388.52M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
39.42
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.31
Financials (FY)
Revenue (FY)
$14.20M+29.15%
Net Income (FY)
−$49.59M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
83.20M
1-Year Return
+264.84%
Dividend and dates
Earnings Date
November 11, 2026estimated
Avg Volume
1.08M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

IRD Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+132.34%
2025+68.91%
2024−60.47%
2023−14.73%
2022−5.36%
2021−42.53%
2020−15.05%
2019−82.89%
2018−53.96%
2017+44.29%
2016 (partial year)−48.15%

As of September 4, 2026.

IRD Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$14.20M−$49.59M−349.3%
2024$10.99M−$57.53M−523.4%
2023$19.05M−$9.99M−52.4%
2022$39.85M$17.89M44.9%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$14.20M—−$38.60M−$49.59M−349.3%
2024$10.99M—−$34.07M−$57.53M−523.4%
2023$19.05M—−$10.56M−$9.99M−52.4%
2022$39.85M—$18.23M$17.89M44.9%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

IRD Valuation vs Biotechnology Median

Median of 656 stocks
MetricIRDBiotechnology medianvs median
P/S ratio39.4215.26158% above
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Opus Genetics, Inc. (IRD) carries a market capitalisation of $388.52M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 27.

Over the past 52 weeks the price has ranged from $1.24 to $5.81. The most recent close on file for IRD is $4.67, dated September 4, 2026. That is +$0.07 (+1.52%) against the previous close. The latest close sits 276.61% above that 52-week low.

Financial Health

In fiscal 2025, Opus Genetics, Inc. reported revenue of $14.20M. Against the prior fiscal year total of $10.99M, that is a change of +29.15%. The same year closed with a net loss of $49.59M. Profit margin runs at 0%. Trailing earnings per share are −1.31.

Across the 4 fiscal years on file, revenue moves from $39.85M in 2022 to $14.20M in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 39.42. On price-to-sales that is 158.26% above the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

The reported beta is 0.58. Daily returns over the trailing 10 years annualize to a volatility of 85.47%. The trailing one-year price return is +264.84%. Measured over 10 years, that is −28.00% a year compounded.

Growth & Income

No dividend is on file for IRD.

The strongest complete calendar year on file is 2025 at +68.91%; the weakest is 2019 at −82.89%. Of the 9 complete calendar years on file, 2 finished higher. So far in 2026 the price is +132.34%.

Peer Comparison

Opus Genetics, Inc. (IRD) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Opus Genetics, Inc. IRD $388.52M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Opus Genetics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Opus Genetics, Inc.

Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-clinical IRD programs, including OPGx-RHO, a gene therapy that targets autosomal dominant retinitis pigmentosa caused by RHO mutations; OPGx-RDH12 that is designed to restore protein expression and halt functional deterioration in patients with retinal dystrophy caused by mutations in the retinal dehydrogenase gene; OPGx-MERTK, an AAV vector for the treatment of MERTK IRD; OPGx-NMNAT1, a gene augmentation therapy designed to halt functional deterioration in pediatric patients with retinal degenerative disease caused by mutations in the nicotinamide mononucleotide adenylyltransferase 1 gene; and OPGx-CNGB1, an AAV gene therapy for retinitis pigmentosa due to mutations in the CNGB1 gene. In addition, it develops Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as for the treatment of presbyopia and dim light or night vision disturbances and APX3330, a small-molecule inhibitor of Ref-1 for the treatment of diabetic retinopathy. Opus Genetics, Inc. was formerly known as Ocuphire Pharma, Inc. and changed its name to Opus Genetics, Inc. in November 2020. The company was founded in 2018 and is headquartered in Durham, North Carolina.

Visit website →